Publication
Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes
Journal Paper/Review - Apr 1, 2007
Schimke Katrin-Elisabeth, Davis Timothy M E
Units
PubMed
Citation
Schimke K, Davis T. Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes. Current opinion in investigational drugs (London, England : 2000) 2007; 8:338-44.
Type
Journal Paper/Review (English)
Journal
Current opinion in investigational drugs (London, England : 2000) 2007; 8
Publication Date
Apr 1, 2007
Issn Print
1472-4472
Pages
338-44
Brief description/objective
Daiichi Sankyo Inc is developing rivoglitazone, an insulin sensitizer with peroxisome proliferator-activated receptor gamma agonistic activity, for the potential treatment of type 2 diabetes. By March 2006, phase I/III clinical trials were underway in the US and the EU.